February 25, 2026 4:48pm

As sellers versus buyers tick it out ending with a barely positive close

“Uncle algo and his electronic trading dwarfs” are lurking smelling some profiteering

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

 

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: Get some or recalibrate? … https://www.regmedinvestors.com/articles/14327

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Wednesday: The Dow closed UP +307.65 points or +0.63%, the S&P closed UP +56.06 points or +0.81% while the Nasdaq closed UP +288.396 points or +1.26%

  • Theme of the session: software and Ai firms are bouncing back helping markets

Wednesday’s (my) 40-company covered sector’s advance/decline line opened positive with 22 incliners, 16 decliners and 2 flats, ending with a BARELY positive close of 20 incliners, 19 decliners and 1 flat

The CBOE Fear (VIX) index, Wednesday closed at 17.89, after Tuesday’s 19.61, Monday’s 21.01, Friday’s 19.11, Thursday’s 20.28 and last Wednesday’s 19.64

Metrics: Wednesday …

  • The RUT was up +11.00 points or +0.41%,
  • The XLV was down -0.04 points or -0.03%,
  • The NBI was down -31.40 points or -0.52%;
  • The XBI was down -0.88 points or -0.68%
  • The IWM was up +1.24 or +0.47%;
  • The IBB was down -1.06 points or -0.60%,
  • The VIX was down -1.66 points or -8.49% at to 17.89

 

Q1/26 February – 1 market holiday, 7 negative and 10 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (10 of 20) 

  • Supernus Therapeutics (SUPN +$3.02 after Tuesday’s +$2.61 after Monday’s -$0.17 after Friday’s -$0.49),
  • Moderna (MRNA +$0.85),
  • uniQure NV (QURE +$0.79 after Tuesday’s -$0.43 after Monday’s +$1.03 after Friday’s -$0.97),
  • Dyne Therapeutics (DYN +$0.55),
  • Wave Life Sciences (WVE +$0.52),
  • Entrada Therapeutics (TRDA +$0.50),
  • Regenxbio (RGNX +$0.45),
  • Capricor Therapeutics (CAPR +$0.44),
  • Lenz Therapeutics (LENZ +$0.40 after Tuesday’s +$0.93 after Monday’s +$0.30 after Friday’s -$0.46),
  • Mesoblast (MESO +$0.39 after Tuesday’s -$0.16 after Monday’s -$0.20),

Flat (1)

  • Generation Bio (GBIO) – acquired

Wednesday’s Closing DOWN (10 of 19): Can you see some of Thursday's moves?

  • Alnylam Pharmaceuticals (ALNY -$5.71 after Tuesday’s  +$3.50 after Monday’s -$6.84 after Friday’s -$3.18),
  • Vertex (VRTX -$4.60 after Tuesday’s +$6.42 after Monday’s +$4.11 after Friday’s +$7.63),
  • Ionis Pharmaceuticals (IONS -$4.52 after Tuesday’s +$0.85 after Monday’s +$1.45 after Friday’s +$0.01),
  • IQIA Holdings (IQV -$3.80 after Tuesday’s +$2.56 after Monday’s -$3.51 after Friday’s -$3.67),
  • Beam Therapeutics (BEAM -$2.68 after Tuesday’s +$3.96 after Monday’s +$0.74 after Friday’s -$0.29),
  • Arrowhead Pharmaceuticals (ARWR -$2.05),
  • CRISPR Therapeutics (CRSP -$1.57 after Tuesday’s+$2.79 after Monday’s +$0.52 after Friday’s -$1.18),
  • AxoGen (AXGN -$1.28 after Tuesday’s -$2.88),
  • Vericel (VCEL -$1.16 after Tuesday’s $0.00),
  • BioNTech (BNTX -$1.05 after Tuesday’s+$0.96 after Monday’s -$0.21),

 

The Bottom Line: More of the … WHY

Indexes rose Wednesday, with … software stocks leading the way, surprise, surprise - again!

  • Hey, it's been a gap-and-go day for the Nasdaq which is having one of its best days in a couple weeks. It jumped over its 20-day moving average this morning and is now heading for its 50-day around 23,250.

An appropriate quote, ““The market is, I think, moving from just throw everything into one category and make it go up to being a little bit more discerning as to which companies might be better positioned than others,” he said. He also said that he believes the “sell-first, ask-questions-later” market is in the “ask-questions-later” phase where “things maybe are not quite so scary.” <CNBC>

Also, “The weakness of the Magnificent Seven stocks is spoiling sentiment at a time when a broadening market should theoretically cheer investors, according to Piper Sandler.

  • “Consider the years 2023-2025, when these mega-caps surged and lifted the S&P 500 to new highs while most stocks severely lagged behind or even declined in some cases. Back then, equity sentiment was generally bullish as the index continued to move higher,” wrote Michael Kantrowitz, chief investment strategist at Piper Sandler.
  • “Today, it feels like the opposite,” he continued. “While we’re seeing the strongest global and domestic equity breadth in many years, the weakness of the Mag 7 stocks are spoiling the party for some.” <CNBC>

 

More earnings this week and coming…

Earnings release dates:

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 4th week

  • 2/25 - Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
  • 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
  • 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

February – 3rd week

  • 2/20 - Friday closed negative with 13 incliners, 26 decliners and 1 flat
  • 2/19 – Thursday closed positive with 25 incliners, 12 decliners and 3 flats
  • 2/18 - Wednesday closed positive with 30 incliners, 8 decliners and 2 flats
  • 2/17 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 2/16 – Monday was market holiday

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: Supernus Therapeutics (SUPN), Moderna (MRNA) and uniQure NV (QURE)
  • Tuesday: Vertex (VRTX), Beam Therapeutics (BEAM) and Alnylam Pharmaceuticals (ALNY)  
  • Monday: Vertex (VRTX), Ionis Pharmaceuticals (IONS) and uniQure NV (QURE)
  • Friday: Vertex (VRTX), Ultragenyx Pharmaceuticals (RARE) and Wave Life Sciences (WVE)

The worst three (3) in the session: Losers

  • Wednesday: Ionis Pharmaceuticals (IONS), Vertex (VRTX) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: AxoGen (AXGN), uniQure NV (QURE), and BioLife Solutions (BLFS)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Sarepta Therapeutics (SRPT)
  • Friday: IQIA Holdings (IQV), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.